title: Obinutuzumab: the more the merrier?
abstract: In this issue of Blood, Byrd et al present data from a randomized phase 2 study in which 78 previously untreated patients with chronic lymphocytic leukemia (CLL) received 8 cycles of either 1000 mg (the current standard dose) or 2000 mg of the anti-CD20 monoclonal antibody (mAb) obinutuzumab. The authors report a higher overall response rate with higher doses of obinutuzumab (67% vs 49%), but there was no significant difference in progression-free survival (PFS) between groups.
authors.affiliation: THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
authors.forename: Jan A
authors.identifier: http://orcid.org/0000-0002-6177-7572
authors.initials: JA
authors.lastname: Burger
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents